title: Anandamide inhibits nuclear factor-kappaB activation through a cannabinoid receptor-independent pathway.
abstract: Anandamide (arachidonoylethanolamine, AEA), an endogenous agonist for both the cannabinoid CB(1) receptor and the vanilloid VR1 receptor, elicits neurobehavioral, anti-inflammatory, immunomodulatory, and proapoptotic effects. Because of the central role of nuclear factor-kappaB (NF-kappaB) in the inflammatory process and the immune response, we postulated that AEA might owe some of its effects to the suppression of NF-kappaB. This study shows that AEA inhibits tumor necrosis factor-alpha (TNFalpha)-induced NF-kappaB activation by direct inhibition of the IkappaB kinase (IKK)beta and, to a lesser extent, the IKKalpha subunits of kappaB inhibitor (IkappaB) kinase complex, and that IKKs inhibition by AEA correlates with inhibition of IkappaBalpha degradation, NF-kappaB binding to DNA, and NF-kappaB-dependent transcription in TNFalpha-stimulated cells. AEA also prevents NF-kappaB-dependent reporter gene expression induced by mitogen-activated protein kinase kinase kinase and NF-kappaB-inducing kinase. The NF-kappaB inhibitory activity of AEA was independent of CB(1) and CB(2) activation in TNFalpha-stimulated 5.1 and A549 cell lines, which do not express vanilloid receptor 1, and was not mediated by hydrolytic products formed through the activity of the enzyme fatty acid amide hydrolase. Chemical modification markedly affected AEA inhibitory activity on NF-kappaB, suggesting rather narrow structure-activity relationships and the specific interaction with a molecular target. Substitution of the alkyl moiety with less saturated fatty acids generally reduced or abolished activity. However, replacement of the ethanolamine "head" with a vanillyl group led to potent inhibition of TNFalpha-induced NF-kappaB-dependent transcription. These findings provide new mechanistic insights into the anti-inflammatory and proapoptotic activities of AEA, and should foster the synthesis of improved analogs amenable to pharmaceutical development as anti-inflammatory agents.
authors.affiliation: Departamento de Biología Celular, Fisiología e Inmunología, Universidad de Córdoba, Facultad de Medicina, Córdoba, Spain.
authors.forename: Rocío
authors.initials: R
authors.lastname: Sancho
authors.forename: Marco A
authors.initials: MA
authors.lastname: Calzado
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Di Marzo
authors.forename: Giovanni
authors.initials: G
authors.lastname: Appendino
authors.forename: Eduardo
authors.initials: E
authors.lastname: Muñoz
mesh_terms: D000581:Amidohydrolases / Q000378:metabolism; D001095:Arachidonic Acids / Q000737:chemistry / Q000494:pharmacology*; D002121:Calcium Channel Blockers / Q000494:pharmacology; D002460:Cell Line; D063388:Endocannabinoids; D004789:Enzyme Activation; D006801:Humans; D051550:I-kappa B Kinase; D020672:I-kappa B Proteins / Q000378:metabolism; D048728:MAP Kinase Kinase Kinase 1; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism*; D053284:Polyunsaturated Alkamides; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000378:metabolism*; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection; D000097782:NF-kappaB-Inducing Kinase; D000099252:Fatty Acid Amide Hydrolases
chemical_list: D000581:Amidohydrolases; D001095:Arachidonic Acids; D002121:Calcium Channel Blockers; D063388:Endocannabinoids; D051550:I-kappa B Kinase; D020672:I-kappa B Proteins; D048728:MAP Kinase Kinase Kinase 1; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B; D053284:Polyunsaturated Alkamides; D017346:Protein Serine-Threonine Kinases; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D000097782:NF-kappaB-Inducing Kinase; D000099252:Fatty Acid Amide Hydrolases; C000606204:NFKBIA protein, human; C496559:CHUK protein, human; C496560:IKBKB protein, human; C496565:IKBKE protein, human; C482576:MAP3K1 protein, human; C078814:anandamide